P9L1

General

Cell Line

hPSCreg name RCMGi008-A
Cite as:
RCMGi008-A (RRID:CVCL_C0C5)
Alternative name(s)
P9L1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RCMGi002-A
(P7L2)
Donor diseases:
Cystic Fibrosis
RCMGi007-A
(P8L2)
Donor diseases:
Cystic Fibrosis
RCMGi004-A
(P6L2)
Donor diseases:
Cystic Fibrosis
RCMGi013-A
(P2L2)
Donor's gene variants:
CFTR
Donor diseases:
Cystic Fibrosis
RCMGi005-A
(P5L1)
Donor diseases:
Cystic Fibrosis
RCMGi001-A
(P1L5)
Donor diseases:
Cystic Fibrosis
RCMGi005-B
(P5L5)
Donor diseases:
Cystic Fibrosis
RCMGi004-B
(P6L8)
Donor diseases:
Cystic Fibrosis
ULBe004-A
(ERAMUC-1)
Donor diseases:
Cystic Fibrosis
IGGi002-A
Donor diseases:
Cystic Fibrosis
INSRMe008-A
(STR-I-203-CFTR)
Donor diseases:
Cystic fibrosis
INSRMe009-A
(STR-I-251-CFTR)
Donor diseases:
Cystic fibrosis
VUBe004-A
(VUB04_CF)
Donor diseases:
Cystic fibrosis
MUBi002-A
(CF 001)
Donor diseases:
Cystic fibrosis
HADe002-A
(HAD 2)
Donor diseases:
Cystic fibrosis
RGIe156-A
(SI-257)
Donor diseases:
Cystic fibrosis
KCLe003-A
(KCL-003-CF-1)
Donor diseases:
Cystic fibrosis
TNRMCi001-A
(iTAF32)
Donor's gene variants:
CFTR
Donor diseases:
Cystic fibrosis
MHHi002-A
(CF(1)iPS5)
Donor diseases:
Cystic fibrosis
MHHi003-A
(CF(15)iPS10)
Donor diseases:
Cystic fibrosis
MHHi004-A
(CF(16)iPS1)
Donor diseases:
Cystic fibrosis
MHHi005-A
(CF(17)iPS6)
Donor diseases:
Cystic fibrosis
BBANTWi007-A
(iPSC_BrS10_FB_C3)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome 1
LUMCi027-A
(LUMC0153iPKP03)
Donor's gene variants:
PKP2
Donor diseases:
arrhythmogenic right ventricular dysplasia 9
Last update 25th January 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Research Centre for Medical Genetics (RCMG)

External Databases

BioSamples SAMEA14092090
Cellosaurus CVCL_C0C5
Wikidata Q114312779

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 20-24
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Cystic Fibrosis
  • cystic fibrosis

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA14092091

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? FSBSI RCMG Ethics Committee
Approval number Protocol # 1 from 28.01.2016
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? FSBSI RCMG Ethics Committee
Approval number Protocol # 1 from 28.01.2016
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Age of donor (at collection) 20-24
Collected in 2019

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SOX2
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
alpha fetoprotein
Yes
Morphology
alpha fetoprotein
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Desmin
Yes
Vimentin
Yes
Morphology
desmin
vimentin (red)
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes
Morphology
TUBB3 (green)

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 16
Karyotyping method: G-Banding

Other Genotyping (Cell Line)